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On average it takes 12 years and a billion euros to develop
a new medicinal product from first discovery to availability
for patients. Especially in the later stages of development,
when promising phase 2 data are available it is difficult to
accept for patients there is no general access. In order to
make medicines available at an earlier stage and to opti-
mise their development, new ways of taking medicines
through the assessment procedures for registration and
reimbursement are highly needed.
A new pilot, called adaptive [1,2] will start soon under
responsibility of the European Medicines Agency. The
idea behind is to give promising products marketing
authorisation in a much earlier stage and collect more
data, not only on safety but also on efficacy, after the
product is on the market.
The biggest advantage is the early access for patients. In
addition collection of data on efficacy on the daily use of
the product (which might be different from the use in the
preselected population in clinical studies) will give a better
idea of the optimal use of the product in that daily setting.
However, there are some downsides as well: what if a pro-
duct after registration turns out not to be as good as we
thought? Might this lead to stop of reimbursement or
even withdrawal of the product and what would that
mean for patients who are benefitting from the treatment?
Secondly, we do already see now that reimbursement
agencies and payers are not always convinced of the added
value of newly registered products and decide not to reim-
burse. What would happen if products come to the market
in a less mature stage? Would industry be prepared to
launch their product at a lower price, since there is less
robust evidence collected on their products? Would there
be even more unequal access between European member
states, reimbursement in some but not all?
The current system is no longer sustainable, so we need
to start with these pilots. But we need to do it carefully,
evaluating the pitfalls along the way, involving patients
and physicians from the start as well as reimbursement
agencies and payers. And we need to openly and honestly
discuss the risks as mentioned above as well.
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